These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30275170)

  • 1. Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product.
    Max WB; Sung HY; Lightwood J; Wang Y; Yao T
    Tob Control; 2018 Nov; 27(Suppl 1):s82-s86. PubMed ID: 30275170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IQOS: examination of Philip Morris International's claim of reduced exposure.
    St Helen G; Jacob Iii P; Nardone N; Benowitz NL
    Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
    Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J
    Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Modeling of Modified Risk Tobacco Products Accounting for Smoking Reduction and Gradual Transitions of Relative Risk.
    Poland B; Teischinger F
    Nicotine Tob Res; 2017 Nov; 19(11):1277-1283. PubMed ID: 28371856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach to assess the population health impact of introducing a Modified Risk Tobacco Product.
    Weitkunat R; Lee PN; Baker G; Sponsiello-Wang Z; González-Zuloeta Ladd AM; Lüdicke F
    Regul Toxicol Pharmacol; 2015 Jun; 72(1):87-93. PubMed ID: 25819932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a hypothetical modified risk tobacco product claim on heated tobacco product use intention and perceptions in young adults.
    Chen-Sankey JC; Kechter A; Barrington-Trimis J; McConnell R; Krueger EA; Cruz TB; Unger JB; Chaffee BW; Leventhal A
    Tob Control; 2023 Jan; 32(1):42-50. PubMed ID: 34059552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
    Lempert LK; Bialous S; Glantz S
    Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
    Robichaud MO; Puryear T; Cohen JE; Kennedy RD
    Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the preclinical risk profile of inhalable candidate and potential candidate modified risk tobacco products: A bridging use case.
    Schlage WK; Titz B; Iskandar A; Poussin C; Van der Toorn M; Wong ET; Pratte P; Maeder S; Schaller JP; Pospisil P; Boue S; Vuillaume G; Leroy P; Martin F; Ivanov NV; Peitsch MC; Hoeng J
    Toxicol Rep; 2020; 7():1187-1206. PubMed ID: 32995294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smokers' Exposure to Perceived Modified Risk Claims for E-Cigarettes, Snus, and Smokeless Tobacco in the United States.
    Wackowski OA; O'Connor RJ; Pearson JL
    Nicotine Tob Res; 2021 Feb; 23(3):605-608. PubMed ID: 32812028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and patterns of tobacco and/or nicotine product use in Japan (2017) after the launch of a heated tobacco product (
    Afolalu EF; Langer P; Fischer K; Roulet S; Magnani P
    F1000Res; 2021; 10():504. PubMed ID: 35528952
    [No Abstract]   [Full Text] [Related]  

  • 17. IQOS print magazine advertising characteristics and reach before and after FDA authorisation as a modified risk tobacco product.
    Ganz O; Strasser AA; Giovenco DP; Audrain-McGovern J; Cappella JN; Safi Z; Tan ASL; Talbot EM; Delnevo CD
    Tob Control; 2023 Mar; ():. PubMed ID: 36958825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults.
    Kim J; Yu H; Lee S; Paek YJ
    Tob Control; 2018 Nov; 27(Suppl 1):s74-s77. PubMed ID: 30158210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heated tobacco product regulation under US law and the FCTC.
    Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s118-s125. PubMed ID: 30291201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of IQOS introduction on Philip Morris International cigarette sales in Spain: a Logarithmic Mean Divisa Index decomposition approach.
    Golpe AA; Martín-Álvarez JM; Galiano A; Asensio E
    Gac Sanit; 2022; 36(4):293-300. PubMed ID: 35219532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.